Delta-opioid receptor activation promotes mesenchymal stem cell survival via PKC/STAT3 signaling pathway

Sayaka Higuchi, Masaaki Ii, Ping Zhu, Muhammad Ashraf

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: The survival of stem cells upon transplantation into ischemic myocardium is a major concern in cellbased therapy. In this study, we tested the hypothesis that activation of opioid receptors would enhance the survival of mesenchymal stem cells (MSCs) upon exposure to an injury stimulus. Methods and Results: MSCs were obtained from rat bone marrow and cultured in basal DMEM cell culture medium. Delta-opioid receptor (DOR) was present in MSCs as examined by reverse transcription-polymerase chain reaction and immunochemistry. Activation of DOR with 5 μmol/L SNC80 (DOR agonist) for 24 h significantly enhanced MSC viability upon exposure to 5 μg/ml actinomycin D as determined by TUNEL and MTT assays. The cytoprotection was abolished with 20 μmol/L naltrindole hydrochloride (a DOR antagonist). Treatment of the cells with 1.5 μmol/L chelerythrine (protein kinase C inhibitor) and 1.25 μmol/L WP1066 (signal transducer and activator of transcription 3 (STAT3) inhibitor) blocked SNC80-induced cytoprotection. Furthermore, treatment of the cells with chelerythrine also blocked STAT3-phosphorylation and Mcl-1 gene expression. Conclusions: Taken together, the results indicate that DOR plays a critical role in MSC survival upon exposure to actinomycin D through activation of protein kinase C and its downstream signaling molecules STAT3 and Mcl-1. DOR may be a novel therapeutic target for stem cell survival during cell-based therapy.

Original languageEnglish (US)
Pages (from-to)204-212
Number of pages9
JournalCirculation Journal
Volume76
Issue number1
DOIs
StatePublished - Jan 1 2012
Externally publishedYes

Fingerprint

STAT3 Transcription Factor
delta Opioid Receptor
Mesenchymal Stromal Cells
Cell Survival
naltrindole
Cytoprotection
Dactinomycin
Protein Kinase C
Immunochemistry
Narcotic Antagonists
Protein C Inhibitor
In Situ Nick-End Labeling
Opioid Receptors
Stem Cell Transplantation
Therapeutics
Protein Kinase Inhibitors
Cell- and Tissue-Based Therapy
Reverse Transcription
Culture Media
Myocardium

Keywords

  • Apoptosis
  • Delta-opioid receptor
  • Mcl-1
  • Mesenchymal stem cells
  • Protein kinase C
  • STAT3

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Delta-opioid receptor activation promotes mesenchymal stem cell survival via PKC/STAT3 signaling pathway. / Higuchi, Sayaka; Ii, Masaaki; Zhu, Ping; Ashraf, Muhammad.

In: Circulation Journal, Vol. 76, No. 1, 01.01.2012, p. 204-212.

Research output: Contribution to journalArticle

@article{d4a28fcf8f1348118d5167f4c93c50fe,
title = "Delta-opioid receptor activation promotes mesenchymal stem cell survival via PKC/STAT3 signaling pathway",
abstract = "Background: The survival of stem cells upon transplantation into ischemic myocardium is a major concern in cellbased therapy. In this study, we tested the hypothesis that activation of opioid receptors would enhance the survival of mesenchymal stem cells (MSCs) upon exposure to an injury stimulus. Methods and Results: MSCs were obtained from rat bone marrow and cultured in basal DMEM cell culture medium. Delta-opioid receptor (DOR) was present in MSCs as examined by reverse transcription-polymerase chain reaction and immunochemistry. Activation of DOR with 5 μmol/L SNC80 (DOR agonist) for 24 h significantly enhanced MSC viability upon exposure to 5 μg/ml actinomycin D as determined by TUNEL and MTT assays. The cytoprotection was abolished with 20 μmol/L naltrindole hydrochloride (a DOR antagonist). Treatment of the cells with 1.5 μmol/L chelerythrine (protein kinase C inhibitor) and 1.25 μmol/L WP1066 (signal transducer and activator of transcription 3 (STAT3) inhibitor) blocked SNC80-induced cytoprotection. Furthermore, treatment of the cells with chelerythrine also blocked STAT3-phosphorylation and Mcl-1 gene expression. Conclusions: Taken together, the results indicate that DOR plays a critical role in MSC survival upon exposure to actinomycin D through activation of protein kinase C and its downstream signaling molecules STAT3 and Mcl-1. DOR may be a novel therapeutic target for stem cell survival during cell-based therapy.",
keywords = "Apoptosis, Delta-opioid receptor, Mcl-1, Mesenchymal stem cells, Protein kinase C, STAT3",
author = "Sayaka Higuchi and Masaaki Ii and Ping Zhu and Muhammad Ashraf",
year = "2012",
month = "1",
day = "1",
doi = "10.1253/circj.CJ-11-0309",
language = "English (US)",
volume = "76",
pages = "204--212",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "1",

}

TY - JOUR

T1 - Delta-opioid receptor activation promotes mesenchymal stem cell survival via PKC/STAT3 signaling pathway

AU - Higuchi, Sayaka

AU - Ii, Masaaki

AU - Zhu, Ping

AU - Ashraf, Muhammad

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Background: The survival of stem cells upon transplantation into ischemic myocardium is a major concern in cellbased therapy. In this study, we tested the hypothesis that activation of opioid receptors would enhance the survival of mesenchymal stem cells (MSCs) upon exposure to an injury stimulus. Methods and Results: MSCs were obtained from rat bone marrow and cultured in basal DMEM cell culture medium. Delta-opioid receptor (DOR) was present in MSCs as examined by reverse transcription-polymerase chain reaction and immunochemistry. Activation of DOR with 5 μmol/L SNC80 (DOR agonist) for 24 h significantly enhanced MSC viability upon exposure to 5 μg/ml actinomycin D as determined by TUNEL and MTT assays. The cytoprotection was abolished with 20 μmol/L naltrindole hydrochloride (a DOR antagonist). Treatment of the cells with 1.5 μmol/L chelerythrine (protein kinase C inhibitor) and 1.25 μmol/L WP1066 (signal transducer and activator of transcription 3 (STAT3) inhibitor) blocked SNC80-induced cytoprotection. Furthermore, treatment of the cells with chelerythrine also blocked STAT3-phosphorylation and Mcl-1 gene expression. Conclusions: Taken together, the results indicate that DOR plays a critical role in MSC survival upon exposure to actinomycin D through activation of protein kinase C and its downstream signaling molecules STAT3 and Mcl-1. DOR may be a novel therapeutic target for stem cell survival during cell-based therapy.

AB - Background: The survival of stem cells upon transplantation into ischemic myocardium is a major concern in cellbased therapy. In this study, we tested the hypothesis that activation of opioid receptors would enhance the survival of mesenchymal stem cells (MSCs) upon exposure to an injury stimulus. Methods and Results: MSCs were obtained from rat bone marrow and cultured in basal DMEM cell culture medium. Delta-opioid receptor (DOR) was present in MSCs as examined by reverse transcription-polymerase chain reaction and immunochemistry. Activation of DOR with 5 μmol/L SNC80 (DOR agonist) for 24 h significantly enhanced MSC viability upon exposure to 5 μg/ml actinomycin D as determined by TUNEL and MTT assays. The cytoprotection was abolished with 20 μmol/L naltrindole hydrochloride (a DOR antagonist). Treatment of the cells with 1.5 μmol/L chelerythrine (protein kinase C inhibitor) and 1.25 μmol/L WP1066 (signal transducer and activator of transcription 3 (STAT3) inhibitor) blocked SNC80-induced cytoprotection. Furthermore, treatment of the cells with chelerythrine also blocked STAT3-phosphorylation and Mcl-1 gene expression. Conclusions: Taken together, the results indicate that DOR plays a critical role in MSC survival upon exposure to actinomycin D through activation of protein kinase C and its downstream signaling molecules STAT3 and Mcl-1. DOR may be a novel therapeutic target for stem cell survival during cell-based therapy.

KW - Apoptosis

KW - Delta-opioid receptor

KW - Mcl-1

KW - Mesenchymal stem cells

KW - Protein kinase C

KW - STAT3

UR - http://www.scopus.com/inward/record.url?scp=84455203109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84455203109&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-11-0309

DO - 10.1253/circj.CJ-11-0309

M3 - Article

C2 - 22033345

AN - SCOPUS:84455203109

VL - 76

SP - 204

EP - 212

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 1

ER -